Publications by authors named "J Zanis-Neto"
Background: Medication errors are avoidable occurrences that can assume clinically significant dimensions and impose relevant costs to the health system, especially in the context of antineoplastic therapy.
Objective: Assess the clinical significance and economic impacts of a clinical pharmaceutical service. This retrospective study consists of an analysis of pharmacy interventions and drug-related problems found in a review of electronic prescriptions referring to antineoplastic therapy of a public teaching tertiary hospital in Brazil.
Article Synopsis
- Pneumocystis jiroveci pneumonia (PJP) is a rare but serious infection linked to high death rates after hematopoietic stem cell transplantation (HSCT), with incidences reported at 0.63% for allogeneic (allo) and 0.28% for autologous (auto) recipients.
- Risk factors for developing PJP include low lymphocyte levels (lymphopenia) and immune mismatch, with cases occurring from 30 days to over a year post-transplant.
- Patients who contracted PJP showed a significantly higher mortality rate—6.87 times more likely to die compared to matched controls—indicating a need for continued prophylaxis in high-risk recipients.
Background: Morbimortality in patients with dilated idiopathic cardiomyopathy is high, even under optimal medical treatment. Autologous infusion of bone marrow adult stem cells has shown promising preliminary results in these patients.
Objective: Determine the effectiveness of autologous transplantation of bone marrow adult stem cells on systolic and diastolic left ventricular function, and on the degree of mitral regurgitation in patients with dilated idiopathic cardiomyopathy in functional classes NYHA II and III.
Background: Despite advances in the treatment of acute leukemia, many patients need to undergo hematopoietic stem cell transplantation. Recent studies show that early lymphocyte recovery may be a predictor of relapse and survival in these patients.
Objective: To analyze the influence of lymphocyte recovery on Days +30 and +100 post-transplant on the occurrence of relapse and survival.